Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Liabilities and Shareholders Equity (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $106.4 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 55.84% to $106.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $377.4 million through Dec 2025, up 62.04% year-over-year, with the annual reading at $106.4 million for FY2025, 55.84% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $106.4 million at Niagen Bioscience, up from $98.1 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $106.4 million in Q4 2025, with the low at $45.7 million in Q3 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $63.6 million, with a median of $55.0 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity decreased 29.2% in 2022, then soared 73.63% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $57.8 million in 2021, then dropped by 6.54% to $54.1 million in 2022, then increased by 1.68% to $55.0 million in 2023, then rose by 24.22% to $68.3 million in 2024, then surged by 55.84% to $106.4 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $106.4 million, $98.1 million, and $91.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.